ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IQAI Iq-ai Limited

1.35
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes

Dividends

No Dividend Data for IQAI

Top Dividend Posts

Top Posts
Posted at 27/3/2024 16:39 by bad gateway
So's iffy but after recent shenanigans wouldn't be out of place in a sentence with IQAI in it imo.
Posted at 25/3/2024 16:31 by festario
This is no longer selling by brokers, to realise their dodgy fundraising fees, this is PI's throwing their shares on the fire, as they have come to the conclusion that this is worthless now. It probably is, but I suspect that there will be a spike or two along the way, albeit much smaller than in the past, which we can sell in to. All trust seems to have evaporated in IQAI now, and sadly, by association, that includes the directors of IB too.
Posted at 03/2/2024 13:27 by festario
This is a wonderful article for Glioblastoma sufferers, but terrible news for IQAI investors.Basically it looks like Prof Scolyer has developed an immense leap forward in curing this horrific disease, via immunotherapy.Maybe we have backed the wrong horse? https://www.bbc.co.uk/news/world-australia-67870595
Posted at 31/1/2024 12:23 by cliffv69
Well if that's the case they had already exceeded the 30 percent since 20th November 2023 as the overall combined percentage was 31 percent. What ever way you want to make it up it's not an unknown that TB and family will always sell once they see a profit to be made so the fact he likes to use trading more as a personal play, it effects the share price therefore the shareholders. I suggest you buy more and help IQAI get to the next spike.
Posted at 31/1/2024 12:11 by howdlep
As I say, you do not understand how this works. The FAB holding is no longer included in a IQAI holding RNS because TB is no longer a director of FAB. However, as the Brown family have an interest in FAB, the holding is a 'concert party' interest. If you do not believe me, check with the IQAI corporate advisor.
This is why the combined holding cannot go over 30% without an offer being made for the remainder of the shares.
Posted at 24/1/2024 11:17 by festario
To put it differently, the spikes that have been 'created' over the years on IQAI, using outlandish language in RNSs have all proved to be a false dawn.So in reality, knowing this to be true, I can only be annoyed with myself for neglecting to sell at the top, and buy back lower down. Those in the know do it very well, I've not done enough of it.
Posted at 16/1/2024 16:09 by joeblogg2
Just checked TB is 78 years surely he wants IQAI to go big after all these years!!!
Posted at 04/1/2024 13:54 by howdlep
Good to see IQAI have caught up with Kane's earlier tweet. I have supplemented with the fact that the Delta T1 maps are already FDA approved:-
Posted at 04/1/2024 12:03 by festario
I'd never heard of that COO guy, but certainly doesn't come across as some brash, pushy salesman.He's somewhat introverted, but I believe that if the product speaks for itself, the uptake will come.The Bayer guy, he is a practising radiologist too. I hope he has bought a wad of IQAI shares.
Posted at 20/8/2023 19:11 by spurs90
#IQAI #stockpick

#IQAI On Friday afternoon announced a deal for IB Neuro and IB Delta T1 to be embedded in GE HealthCare's (GEHC) MR Smart Subscription. IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance imaging (MRI) data as input and automatically compute quantitative and proprietary images as output.
 
The global MRI market is projected to grow at a rate of 7% and surpass $11 billion by 2030, and GEHC is a leading player in that market. A factor driving that growth are complementary advancements in imaging software, such as IB's quantitative solutions.

Their software is available via the newly launched Bayer Calantic platform.

They also have a drug in phase 1 but have already stated it will be entering phase 2 and this will be funded by a partnership with a major pharmaceutical company. They have recently received orphan drug status for this drug for both adult patients and children for the treatment of glioblastoma(brain cancer). They have recently announced they will be starting a second phase 1 study for children and have initiated discussions with several sites who have expressed a collaborative interest. Paediatric brain tumour research and development receive significant philanthropic funding. Consortiums of non-profits exist that help fund clinical trials for children, either partially or in their entirety. #IQAI have already made connections and introduced their progress to one organization. In turn, they identified several hospitals with whom they have established relationships so we should receive an update imminently for this. The ultimate objective of our program is to obtain regulatory approval for a medicine that could offer a positive impact on the length and quality of life for patients who otherwise have no other options. As the trial process continues, their efforts to identify and secure an accelerated regulatory approval pathway will also continue. Pathways, such as Fast Track Designation and Paediatric Rare Disease Priority Review Voucher (PRD-PRV), exist to expedite the development, review, and approval of promising drugs that treat diseases such as GBM and paediatric cancers.

Paediatric rare disease priority review vouchers have recently sold for over $100m with examples from Sarepta Therapeutics and bluebird bio both selling theirs to major pharmaceutical companies.

#IQAI Also have patented artificial intelligence ("AI") technology, IB Zero G generates enhanced "with contrast" images using only non-contrast (0% gadolinium) images as input. The FDA's response to the FDA 510(k) submission concluded that IB Zero G™ was too novel and unique a product and subsequently directed IB to pursue a different regulatory clearance pathway. IB is compiling additional documentation in preparation for a pre-submission meeting with the FDA and plans to submit a "de novo" application in the second half of the year. The de novo request is a market clearance pathway designed for novel medical devices for which no legally marketed predicate device exists to demonstrate substantial equivalence. So we could receive an update on this imminently also.

#IQAI shares have previously traded as high as 24p and as low as 1p with all this recent positive news announced they could in my opinion be headed back to 20p+ although this time they have a dual listing on the us otc market so we could see new all time highs if it gets picked up over there with the us investors having deeper pockets. There are 183m shares in issue and the ceo holds 29% of these so it’s in his best interest for these to succeed. Currently shares are 3.8/4p giving a market capitalisation of £6.9m. With all these factors and with their footprint in the USA only getting bigger and deals being signed better this share will in my opinion be multiples of today’s price in the very near future.

#IQAI #stockpick
Numbers are end of June.. 

Cash 90k 

Income 282k 

Profit 278k 

Costs 578k (Admin 572k, Finance 5k etc) 

Loss 300k 

Cash used in operations is 224k. 

More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients.
 
It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023. Plus we now have the GE health care network to sell into. GE Health has installed 4 million scanners and other medical devices worldwide. GEHC total assets $28bil. They invest over $1bil annually in R&D. 259k patients supported daily using imaging technology. 2bil patients scanned annually.


Lots to look forward to in regards to upcoming updates

Your Recent History

Delayed Upgrade Clock